Back

The cardiovascular benefit of Lp(a) reduction: not there yet

European Heart Journal

9 November 2020
Organised by: Logo
Read full article
ESC Journals CARDIOVASCULAR PHARMACOLOGY OTHER PREVENTIVE CARDIOLOGY Risk Factors and Prevention Pharmacology and Pharmacotherapy

Abstract

Abstract

Contributors

Angela Pirillo
Angela Pirillo

Author

Alberico Luigi Catapano
Alberico Luigi Catapano

Author

IRCCS - MultiMedica Milan , Italy

You may be interested in
thumbnail
Congress Presentation
Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction and estimating benefits from novel interventions
28 August 2020
thumbnail
ESC TV Today
Episode 26: Lp(a): the future starts now - Myocardial infarction in older age and frailty
6 November 2025
thumbnail
Congress Presentation
Lipoprotein(a) levels and LPA genotypes are not associated with echocardiographic measures of left ventricular structure and function in the general population
1 September 2024
thumbnail
Congress Presentation
Extension of coronary artery disease and resistance to lipid-lowering treatment. Value of Lp(a)
23 April 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources